Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Pechala's Reports
$25.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Novo Nordisk A/S' NovoEight Passes Review by Committee on Drugs of Pharmaceutical Affairs in Japan


Sunday, 17 Nov 2013 07:00pm EST 

Novo Nordisk A/S announced that NovoEight (turoctocog alfa) has passed the review by the Committee on Drugs of Japan's Pharmaceutical Affairs and Sanitation Council. The remaining step in the regulatory process is an official approval from the Ministry of Health, Labour and Welfare (MHLW). The Committee on Drugs serves as an advisory body to the MHLW, in matters related to pharmaceuticals including new drug applications. NovoEight is a recombinant coagulation factor VIII for the treatment of haemophilia A. 

Company Quote

45.53
0.1 +0.22%
11 Jul 2014